Emyria joins NIH HEAL initiative to evaluate ultra-pure cannabinoid formulations
Proactive Investors
Published Nov 28, 2022 10:41
Updated Nov 28, 2022 11:31
Emyria joins NIH HEAL initiative to evaluate ultra-pure cannabinoid formulations
Emyria Ltd (ASX:EMD) has been accepted into the US National Institute of Health’s (NIH) Preclinical Screening Platform for Pain program.
The NIH’s National Institute of Neurological Disorders and Stroke (NINDS) — also the leading funder of neurological research in the US — will run the study as part of a broader initiative to stem the opioid public health crisis.
Launched in April 2018, the NIH HEAL initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, as well as enhancing pain management.
Essentially, the program will evaluate the suitability of Emyria’s proprietary ultra-pure cannabinoid formulations as alternative treatments for pain.
Evaluating unique, pharmaceutical-grade formulations
Emyria managing director Dr Michael Winlo said: “We’re delighted to be accepted into this prestigious program to comprehensively evaluate the suitability of our unique, pharmaceutical-grade formulations to address major unmet needs in pain.
“Our compelling Real World Data has demonstrated that cannabinoids may be useful amongst sufferers of chronic, non-cancer pain and we saw a need to develop reliable, ultra-pure dose forms, suitable for registration with major regulators.”
How does care model reduce opioid use?
Emyria recently charted the oral morphine equivalent daily dose (oMEDD) for a 220-patient cohort of high opioid users at its Emerald Clinics.
oMEDD scores were calculated by examining linked community pharmacy dispensing data from NostraData/IQVIA in the 12 months before and after starting care at Emerald Clinics.
The analysis reveals that these patients had a stable oMEDD scores in the 12 months prior to treatment but experienced a significant average reduction of 30% in their daily oMEDD scores.
Read more on Proactive Investors AU
Disclaimer
Get The App
Written By: Proactive Investors
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.